SecBot SecBot
PRESS-RELEASE ·Filed May 20, 2026

PHAT

Phathom Pharmaceuticals
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

The breadth of independent research supports vonoprazan's scientific credibility, but no immediate catalyst for stock movement. Monitor for potential label expansion or competitive positioning based on future regulatory actions.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$11.87
T+0 close · May 20, 2026 · via day close
Latest settled
−19.29%
T+60 · $9.58
Vs SPY
−24.30%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 20 $11.87entry
  2. T+1 · 6mo ago −2.44%α −2.64% · $11.58
  3. T+5 · 6mo ago −9.52%α −10.76% · $10.74
  4. T+20 · 5mo ago −8.34%α −9.08% · $10.88
  5. T+60 · 3mo ago −19.29%α −24.30% · $9.58
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Phathom Pharmaceuticals announced the presentation of 31 vonoprazan-related abstracts at DDW 2026, including a Phathom-sponsored analysis from the Phase 3 pHalcon-NERD-301 study recognized as a Poster of Distinction. The data covers GERD, H. pylori eradication, long-term safety, and post-endoscopic care, but no new regulatory actions or financial guidance were provided.

Key Facts

  • 31 vonoprazan-related abstracts presented at DDW 2026, including 28 independent investigator-initiated studies
  • Phathom-sponsored analysis from Phase 3 pHalcon-NERD-301 study recognized as Poster of Distinction
  • Data covers GERD, H. pylori eradication, long-term safety, and post-endoscopic submucosal dissection use
  • No new FDA decisions, label expansions, or financial updates announced

Financial Impact

No financial impact from this press release; revenue and guidance unchanged.

Risk Factors

  • Investor expectations for near-term label expansion may be disappointed if no FDA action follows
  • Competitive pressure from PPIs and other PCABs may limit commercial uptake

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3298395

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 20, 2026